Chairman of the board of directors of Asahi Kasei Pharma Denmark A/S, CVR-no.: 40948074.
Mr. Etoh has over 20 years of experience in the pharmaceutical industry, from business development and strategy to drug discovery and development. He also established a CVC investment function in Asahi Kasei Pharma Corporation. Mr. Etoh holds a Ph.D. from Tokyo Medical and Dental University and MSc from Kyushu Institute of Technology.
Masaya Etoh will be an independent board member.
Manager and director of Asahi Kasei Pharma Denmark A/S, CVR-no.: 40948074.
Mr. Matsuo joined Asahi Kasei Pharma Corporation in July 2012 as Manager of Corporate Planning and now General Manager of Corporate Planning. Prior to joining Asahi Kasei Pharma, Mr. Matsuo had been Senior Consultant at Nomura Research Institute for 10 years. In addition, Mr. Matsuo has held commercial banking roles at MUFJ Bank, Ltd for 7 years. Mr. Matsuo holds a Bachelor of Faculty of Commerce from Keio University.
Daisuke Matsuo will be an independent board member.
Dumont Director of Asahi Kasei Pharma Denmark A/S, CVR-no.: 40948074.
Mr. Dumont joined Asahi Kasei Pharma America in April 2019 as Director of Corporate Development. Mr. Dumont has 10 years of commercial experience in business and corporate development within the biopharmaceutical and medical device industries. Prior to joining Asahi Kasei, Mr. Dumont was Director of Strategy and Corporate Development at PerkinElmer, Inc. In addition, Mr. Dumont has held corporate development roles at Mylan Pharmaceuticals and Catalent Pharma Solutions. Mr. Dumont holds a Bachelor and Masters of Science in Chemical Engineering from the Johns Hopkins University and a Master of Business Administration from Columbia University.
Matthew Ryan Dumont will be an independent board member.